US Patent

US9393256 — Methods for treating HCV

Method of Use · Assigned to Gilead Pharmasset LLC · Expires 2032-09-14 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating hepatitis C virus infection using combinations of therapeutic molecules.

USPTO Abstract

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1470`	—
`U-1470`	—
`U-1470`	—
`U-1470`	—

Patent Metadata

Patent number: US9393256
Jurisdiction: US
Classification: Method of Use
Expires: 2032-09-14
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.